Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dexcom Inc (NQ: DXCM )

70.35 -0.13 (-0.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dexcom Inc

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
31 32 Next >
Check Out What Whales Are Doing With DXCM
Via Benzinga
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review
Microsoft, Meta, Cloudflare and Crocs were among the many big movers. 
Via Investor's Business Daily
Roblox And 3 Other Stocks Insiders Are Selling
The Nasdaq Composite closed sharply higher on Thursday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Mastercard To Rally Over 18%? Here Are 10 Other Analyst Forecasts For Friday
Wells Fargo raised the price target for Molina Healthcare, Inc. (NYSE: MOH) from $282 to $290. Wells Fargo analyst Stephen Baxter maintained an Underweight rating. Molina Healthcare shares gained 7.8%... 
Via Benzinga
Top 2% Stock Dexcom Easily Beats First-Quarter Expectations, Boosts Outlook
Dexcom is benefitting from the shift to continuous glucose monitors in diabetes management. 
Via Investor's Business Daily
2 Growth Stocks That Could Double in 5 Years
Both of these companies did more than that in the past five years. 
Via The Motley Fool
DexCom Q1 Earnings Beat Sets Stage For Upcoming Catalysts During 2023, Analyst Says
DexCom Inc (NASDAQ: DXCM) raised its 2023 financial guidance following strong  
Via Benzinga
Dexcom Reports First Quarter 2023 Financial Results
From DexCom, Inc.
Via Business Wire
Dexcom G6 Real-Time CGM System Now Accessible to Any Eligible Client Managing Diabetes With Insulin Through NIHB
From Dexcom, Inc.
Via Business Wire
“Sell In May Effect”: Uncovering Investment Opportunities During Seasonal Weakness
Despite the seasonal weakness that is often associated with the summer months, there are still market opportunities waiting to be uncovered. 
Via Talk Markets
P/E Ratio Insights for DexCom
Via Benzinga
Elliott Wave Technical Analysis: DexCom Inc
Looking for further upside into wave (C) as we have broken through the confirmation level (green line). 
Via Talk Markets
$100 Invested In DexCom 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Where DexCom Stands With Analysts
Via Benzinga
2 Monster Stocks to Buy Without Any Hesitation
These stocks have grown revenue, earnings and share price over the past five years. 
Via The Motley Fool
This Company's Non-Invasive Tech Looks To Be Unique In the Market And Can Help People Take Ownership Over Monitoring Their Health
The need for noninvasive healthcare technology that allows people to take ownership and gather more insight into their health became acute when COVID revealed the fragility of the hospital system.  
Via Benzinga
3 Medtech Companies with Higher Future Share Prices
The analysts see normalization and growth for the med tech industry and have started picking their favorites for 2023 and beyond. 
Via MarketBeat
Stock Market Rally Drifts Lower; Tesla Dives On Margins; ISRG, DHI, LVS Are Winners: Weekly Review
The major indexes saw modest declines, holding in a range. 
Via Investor's Business Daily
What To Know About Raymond James's Upgrade of DexCom
Via Benzinga
The Medicare Decision That Propelled Dexcom Stock Closer To A Breakout
Now, 1.5 million more Americans will have access to CGMs, Dexcom said. 
Via Investor's Business Daily
Diversified Abbott Laboratories Could Reverse And Move Higher
Abbott Laboratories reported a solid quarter driven by gains in the core business that are accelerating as COVID sales decline. 
Via MarketBeat
Exposures COVID-19
Physician Checks And Latest Script Data Support DexCom Growth Opportunity: Bullish Analyst Upgrades Stock
Via Benzinga
Visa To Rally 15%? Here Are 10 Other Analyst Forecasts For Monday
Raymond James boosted the price target for DexCom, Inc. (NASDAQ: DXCM) from $127 to $138. Raymond James analyst Jayson Bedford upgraded the stock from Outperform to Strong Buy. DexCom shares rose 1.8%... 
Via Benzinga
Healthcare Innovation Drives Medical Device Makers To New Highs
Medical products makers Stryker and Boston Scientific are rallying to all-time highs, while sector peer DexCom is forming a constructive base. 
Via MarketBeat
Benzinga's Top Ratings Upgrades, Downgrades For April 17, 2023
Via Benzinga
Dexcom Commends Decision to Expand CGM Medicare Coverage to Include People With Diabetes Using All Types of Insulin
From Dexcom, Inc.
Via Business Wire
2 Stocks That Turned $40,000 Into $1 Million in 10 Years
Are these stocks still good buys today? 
Via The Motley Fool
Elliott Wave Technical Analysis: DexCom Inc. - Tuesday, April 11
We are looking for further upside in wave (C) as we are seeing what appears to be a triangle in wave (B). 
Via Talk Markets
1 Stock-Split Stock That's a Surefire April Buy and 1 to Avoid
One stock-split stock is executing flawlessly and seeing its operating margin climb, while another widely held company is flashing warning signs. 
Via The Motley Fool
A Nasdaq Bull Market Is Coming: 2 Fantastic Stocks to Buy and Hold
Investing is a long-term game, and both of these companies are thinking that way. 
Via The Motley Fool
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.